a few months back, the startup is now the second-highest-funded brain-computer interface company out there with $160 million in capital, trailing only Neuralink itself.
And in spite of the flashy VR concept, overall Hodak has expressed a very cautious vision for the company's trajectory. "The technical approach we're developing is extremely different from what Neuralink was doing," he told us. "Ultimately, though, our vision goes well beyond just clinical visual prostheses. But we want to let ambition grow with success rather than making big statements about things we may or may not do in the future at this point."
For now, Science Corp is "focused on getting our first product into patients" — and once it does, we're excited to see where the startup goes next.
sign me up